All News

Article

LLDAS: Predicting Pregnancy Outcomes

Sheila Reyes, MD

Pregnancy in SLE is a high risk situation and active disease can lead to fetal loss, pre-term birth, IUGR and neonatal lupus syndromes. In a study by Dr. Michelle Petri and colleagues, they evaluated whether the LLDAS at the start of pregnancy was predictive of pregnancy outcome.

Robert B Chao, MD Tweet
doctorRBC
Improvement of enthesitis US scores consistent with bDMARD initiation/change 1⃣MASEI and OMERACT scores improved at 3 mo/6mo 2⃣Associated with clinical activity outcomes @RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
David Liew Tweet
drdavidliew
RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no. Same decline Is 1g q4m dosing not justified? Does that mean RTX needs to be continued, and in whom? #ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
Dr. Rachel Tate Tweet
uptoTate
Did you have diversity and inclusion and/or bias training during fellowship? #ACR20 @RheumNow
Dr. John Cush Tweet
RheumNow
GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?
Dr. John Cush Tweet
RheumNow
When diagnosing Febrile, possible autoinflammatory, Stills disorders do you order genetic testing
MGH Rheumatology Tweet
MGHrheumatology
Congratulations to House of DMARDs, our new @ACRheum 2020 Knowledge Bowl Champions!! 🏆 We are so proud!! @kmdsilvaMD @JonathanDauMD @NasrallahMazen #ACR20 https://t.co/iFaMRNB5D3
The Lancet Rheumatology Tweet
TheLancetRheum
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
Robert B Chao, MD Tweet
doctorRBC
Mavrilimumab (anti GM-CSF receptor α Mab) efficacious in maintaining disease remission in GCA pts. Phase 2 trial (n=70) 1⃣Disease flare 19% in tx vs. 46% in PBO at 26wk 2⃣Sustained remission 83% vs. 50% in PBO 3⃣Similar AE in both groups @RheumNow #ACR20 Abs#L06 https://t.co/LqiNKJffFo
Olga Petryna Tweet
DrPetryna
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
Abst#1717 confirms that early start of csDMARDs as 1st line tx & keeping ts/bDMARD as 2nd line tx (or more) is associated w/ a favorable outcome at 10 yrs in the ESPOIR cohort (a French multi-center cohort that followed patients w/ early RA). #ACR20 @RheumNow https://t.co/bzZiShCF97
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×